-
Eighty-seven percent or more of patients with fatal or nonfatal myocardial infarction have major risk factors prior to the event.
-
Patients with unexplained chronic fatigue and bodily pain are more likely to have rhinosinusitis symptoms than are people in the general population.
-
-
Insulin 70/30 Mix Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and Diabetes
-
Vardenafil has been approved for the treatment of erectile dysfunction in men. The drug is the second oral type 5 phosphodiestase (PDE5) inhibitor approved for this indication along with sildenafil (Viagra).
-
There are arguments about the optimal treatment for ulcers with nonbleeding visible vessels and adherent clots. This study showed that the combination of endoscopic hemostasis with IV proton pump inhibitor therapy is superior to PPI alone in management of such patients.
-
Seasonale (Barr Laboratories, Pomona, NY), the first extended-cycle oral contraceptive (12 weeks continuous daily active pill followed by a one-week inactive pill) approved by the Food and Drug Administration (FDA) is expected to become clinically available by the end of this month.
-
ACNM web site offers breast-feeding resources; New condom now available from Trojan; New Arabic web site offers EC information
-
Just six years ago, a national report asked, Is the secret getting out? when it comes to emergency contraception (EC).1 If results of the 2003 Contraceptive Technology Update Contraception Survey are any indication, ECs message now is being heard loud and clear.
-
The next patient on your schedule is a 41-year-old woman who smokes 12-15 cigarettes a day. She would like to use combined oral contraceptives (OCs). Will she leave your office with a prescription for the Pill?